Related Experiment Videos
Longitudinal assessment of L-thyroxine therapy for congenital hypothyroidism
1Department of Pediatrics, State University of New York, Stony Brook School of Medicine.
Insights
Congenital hypothyroidism in infants is safely and effectively treated with L-thyroxine therapy. Prompt restoration of normal thyroid hormone levels is achieved within one week, ensuring healthy development.
Area of Science:
- Pediatric Endocrinology
- Neonatal Medicine
- Thyroid Disorders
Background:
- Congenital primary hypothyroidism requires timely intervention to prevent developmental issues.
- Understanding the longitudinal response to L-thyroxine therapy is crucial for optimizing treatment.
Purpose of the Study:
- To evaluate the longitudinal response to L-thyroxine therapy in infants with congenital primary hypothyroidism during the first year of treatment.
- To compare the response to therapy based on the etiology of hypothyroidism (thyroid dysgenesis vs. dyshormonogenesis).
Main Methods:
- Longitudinal evaluation of 43 infants diagnosed with congenital primary hypothyroidism.
- Treatment with L-thyroxine at 10–14 µg/kg/day, initiated immediately after diagnosis.
- Serial monitoring of serum thyroid hormone levels (total thyroxine, free thyroxine, triiodothyronine, reverse triiodothyronine) and thyroid-stimulating hormone.
Main Results:
- Serum total and free thyroxine normalized within one week of initiating L-thyroxine therapy in all infants.
- Infants with dyshormonogenesis showed a more sensitive response to initial thyroid hormone replacement compared to those with thyroid dysgenesis.
- The therapeutic dose of 10–14 µg/kg/day L-thyroxine effectively suppressed thyroid-stimulating hormone levels.
Conclusions:
- Prompt restoration of euthyroidism in early infancy using L-thyroxine is safe and effective for congenital hypothyroidism.
- The established therapeutic dosage ensures clinical and biochemical normalization.
- Different etiologies of congenital hypothyroidism may influence the sensitivity to thyroid hormone replacement.
Abstract:
We evaluated the longitudinal response in 43 infants with congenital primary hypothyroidism during the first year of L-thyroxine therapy. Diagnosis was confirmed by serum thyroid hormone measurements by 4 weeks of age in 38 infants and between 40 and 80 days of age in the remainder. This group of infants was divided by radionuclide thyroid imaging into 34 infants with thyroid dysgenesis and nine with dyshormonogenesis. The group with thyroid dysgenesis was subdivided into 21 infants with athyreosis and 13 with residual thyroid tissue (11 ectopic and 2 hypoplastic glands). L-Thyroxine therapy, at an average dose of 10 to 14 micrograms/kg/day, was begun immediately after diagnosis, and serum concentration of total thyroxine, free thyroxine, triiodothyronine, reverse triiodothyronine, and thyroid-stimulating hormone were determined serially. Serum concentration of total and of free thyroxine became normal within 1 week of the start of therapy in all groups. Despite a similarly mild degree of hypothyroidism at diagnosis observed in infants with dyshormonogenesis or with ectopia or hypoplasia, those with dyshormonogenesis had a more sensitive response to initial thyroid hormone replacement than did patients with thyroid dysgenesis, as judged by L-thyroxine does and thyroid-stimulating hormone suppression. We conclude that the prompt restoration of clinical and biochemical euthyroidism during early infancy with doses of L-thyroxine between 10 and 14 micrograms/kg/day is a safe and effective method of therapy for children with congenital hypothyroidism.